Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment
Standard
Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment. / Alzheimer’s Disease Neuroimaging Initiative.
In: J ALZHEIMERS DIS, Vol. 51, No. 3, 2016, p. 867-73.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment
AU - Suppa, Per
AU - Hampel, Harald
AU - Kepp, Timo
AU - Lange, Catharina
AU - Spies, Lothar
AU - Fiebach, Jochen B
AU - Dubois, Bruno
AU - Buchert, Ralph
AU - Alzheimer’s Disease Neuroimaging Initiative
PY - 2016
Y1 - 2016
N2 - MRI-based hippocampus volume, a core feasible biomarker of Alzheimer's disease (AD), is not yet widely used in clinical patient care, partly due to lack of validation of software tools for hippocampal volumetry that are compatible with routine workflow. Here, we evaluate fully-automated and computationally efficient hippocampal volumetry with FSL-FIRST for prediction of AD dementia (ADD) in subjects with amnestic mild cognitive impairment (aMCI) from phase 1 of the Alzheimer's Disease Neuroimaging Initiative. Receiver operating characteristic analysis of FSL-FIRST hippocampal volume (corrected for head size and age) revealed an area under the curve of 0.79, 0.70, and 0.70 for prediction of aMCI-to-ADD conversion within 12, 24, or 36 months, respectively. Thus, FSL-FIRST provides about the same power for prediction of progression to ADD in aMCI as other volumetry methods.
AB - MRI-based hippocampus volume, a core feasible biomarker of Alzheimer's disease (AD), is not yet widely used in clinical patient care, partly due to lack of validation of software tools for hippocampal volumetry that are compatible with routine workflow. Here, we evaluate fully-automated and computationally efficient hippocampal volumetry with FSL-FIRST for prediction of AD dementia (ADD) in subjects with amnestic mild cognitive impairment (aMCI) from phase 1 of the Alzheimer's Disease Neuroimaging Initiative. Receiver operating characteristic analysis of FSL-FIRST hippocampal volume (corrected for head size and age) revealed an area under the curve of 0.79, 0.70, and 0.70 for prediction of aMCI-to-ADD conversion within 12, 24, or 36 months, respectively. Thus, FSL-FIRST provides about the same power for prediction of progression to ADD in aMCI as other volumetry methods.
KW - Aged
KW - Aging/pathology
KW - Alzheimer Disease/diagnostic imaging
KW - Area Under Curve
KW - Cognitive Dysfunction/diagnostic imaging
KW - Databases, Factual
KW - Disease Progression
KW - Hippocampus/diagnostic imaging
KW - Humans
KW - Image Interpretation, Computer-Assisted/methods
KW - Magnetic Resonance Imaging/methods
KW - Neuropsychological Tests
KW - Organ Size
KW - Pattern Recognition, Automated/methods
KW - Prognosis
KW - ROC Curve
KW - Reproducibility of Results
KW - Risk
KW - Sensitivity and Specificity
KW - Time Factors
U2 - 10.3233/JAD-150804
DO - 10.3233/JAD-150804
M3 - SCORING: Journal article
C2 - 26923010
VL - 51
SP - 867
EP - 873
JO - J ALZHEIMERS DIS
JF - J ALZHEIMERS DIS
SN - 1387-2877
IS - 3
ER -